- Medtronic Cryoablation Superior to Drug Therapy for Symptomatic Paroxysmal Atrial Fibrillation
- Medtronic Reports First Quarter Financial Results
- Medtronic Board Appoints Kevin Lofton as a New Director
- Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2021
- Medtronic Evolut TAVR System Receives Updated U.S. Labeling Revising Precaution for Treatment of Low-Risk Patients with Bicuspid Aortic Stenosis
- Medtronic Begins Post-Market, Real-World Study of the InterStim™ Micro System
- Study Published in The New England Journal of Medicine Demonstrates Patients Experience Fewer Disruptions to Dialysis Therapy When Treated with Medtronic Drug-Coated Balloon
- Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2021
- Medtronic to Acquire Smart Insulin Pen Company Companion Medical
- Medtronic Announces Comprehensive U.S. Launch of New InterStim™ Micro Neurostimulator
More ▼
Key statistics
As of last trade Medtronic PLC (MDT3:BUE) traded at 4,504.50, -11.68% below its 52-week high of 5,100.00, set on Oct 26, 2020.
52-week range
Markit short selling activity
Open | 4,550.00 |
---|---|
High | 4,550.00 |
Low | 4,499.00 |
Bid | -- |
Offer | 4,500.00 |
Previous close | 4,504.50 |
Average volume | 8.67 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | 47.36 ARS |
---|---|
Annual div yield (ADY) | 1.05% |
Div ex-date | Dec 21 2020 |
Div pay-date | Jan 15 2021 |
Data delayed at least 20 minutes, as of Mar 04 2021.
More ▼